 | |
| Legal status | |
|---|---|
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C26H24FNO |
| Molar mass | 385.482 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
JWH-368 ([5-(3-Fluorophenyl)-1-pentylpyrrol-3-yl]-naphthalen-1-ylmethanone) is asynthetic cannabinoid from the naphthoylpyrrole family which acts as an agonist of theCB1 (Ki = 16 ± 1nM) andCB2 (Ki = 9.1 ± 0.7nM) receptors, binding ~1.76 times stronger to the CB2 receptor than to the CB1 receptor. JWH-368 was first synthesized in 2006 byJohn W. Huffman and colleagues to examine the nature of ligand binding to theCB1 receptor.[1]
In the United States JWH-368 is not federally scheduled, although some states have passed legislation banning the sale, possession, and manufacture of JWH-368.[2][3][4][5]
In Canada, JWH-368 and other naphthoylpyrrole-based cannabinoids are Schedule II controlled substances under theControlled Drugs and Substances Act.
In the United Kingdom, JWH-368 and other naphthoylpyrrole-based cannabinoids are considered Class B drugs under theMisuse of Drugs Act 1971.
 | Thiscannabinoid related article is astub. You can help Wikipedia byexpanding it. |
